AF
ORMP icon

Atala Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

Atala Financial’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$242 – 476
2024
Q4 		$242 Buy
+100
New +$238 ﹤0.01% 468

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Atala Financial's ORMP Position: Q1 2025 in Review

Atala Financial sold out of Oramed Pharmaceuticals (ORMP) in Q1 2025, closing a stake of 100 shares — an estimated $242 sold.

Atala Financial first reported a position in ORMP in Q4 2024 and held it in 1 quarter. The position peaked at $242 in Q4 2024. 52 funds tracked by Wall St. Rank hold ORMP as of Q1 2025.

  • Atala Financial reported no remaining Oramed Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Atala Financial sold 100 Oramed Pharmaceuticals shares in Q1 2025, an estimated $242.
  • Atala Financial first reported a position in Oramed Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Atala Financial's Oramed Pharmaceuticals position peaked at $242 in Q4 2024.
  • 52 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2025.

Based on Atala Financial's 13F filing for Q1 2025, filed 23 Apr 2025.